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Heart failure (HF) represents a cardiovascular syndrome
of major importance with increasing prevalence world-
wide contributing to increased cardiovascular morbidity
and mortality. The hallmarks of this syndrome in
response to myocardial dysfunction are intense systemic
and renal vasoconstriction, avid sodium and water reten-
tion and structural remodelling of the heart which all con-
tribute to the symptoms and signs of this disease process.
Both from a pathophysiological and therapeutic perspec-
tive, the cGMP pathway plays a central role with great
opportunity for therapeutic modulation. Two interacting
cGMP pathways are central to the emerging therapeutics
of HF. One is the NO/sGC/cGMP system and the other is
the Natriuretic peptide (NP)/pGC/cGMP system. Increas-
ing evidence establishes that the intense vasoconstriction
of HF involves a dysfunctional NO/sGC/cGMP with evi-
dence for excessive oxidized and heme free sGC rendering
this important vasorelaxing system markedly impaired.
We have demonstrated the novel NO-independent and
heme-independent sGC stimulator BAY 58–2667 has
potent systemic and renal vasodilating actions, unloads
the heart, increases cardiac output and preserves GFR and
sodium excretion. Unlike conventional nitrovasodilators
BAY 58–2667 is a selective sGC activator that has no
cGMP-independent actions and lacking tolerance repre-
sents a landmark breakthrough as a novel new agent for
HF via NO/sGC/cGMP signalling. With regard to the com-
plementary NP/pGC/cGMP pathway, both cardiac pep-
tides ANP and BNP that target the pGC-A receptor have
been developed for HF. Due in part to distinct spatial and
temporal localization of sGC versus pGC receptors and
signalling in the kidney, NP/pGC/cGMP signalling in the
kidney more importantly regulates GFR and sodium
excretion whereas the NO/sGC/cGMP pathway more
importantly controls renal vascular tone. Here however
the full renal actions of ANP and BNP are limited by
upregulation of renal type V phosphodiesterase (PDEV)
and dual targeting of pGC-A with BNP together with
PDEV inhibition with sildenafil results in marked restora-
tion of NP/pGC/cGMP activation resulting in enhanced
GFR and sodium excretion together with PDEV inhibition
suppressing ventricular hypertrophy. Recognizing the
recent report of pGC-A receptor downregulation in the
kidney and heart in HF, novel new generation chimeric
peptides of CNP that possess additional renal actions are
emerging as complementary cGMP strategy to enhance
cardiovascular and renal function in the syndrome of HF.
Finally, the concept of activating both pGC with a NP and
sGC with BAY 58–2667 is also emerging to optimize car-
diorenal function and enhance cardiovascular structure.
Clearly, cGMP modulation is proving to be a seminal
advance in the therapeutics of HF which is a cardiovascu-
lar syndrome with major unmet therapeutic needs.
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